The World Health Organisation (WHO) has expressed hope that the Ebola outbreak in the Democratic Republic of the Congo (DRC) can be contained, despite confirmed cases of Bundibugyo virus disease surpassing 10,000.
The optimism comes as data released by the DRC’s Ministry of Public Health on Tuesday put confirmed cases at 10,060, with 4,887 deaths, according to a reportby Al Jazeera.
The outbreak, declared on 15 May, is the largest and deadliestEbola epidemic recorded in the DRC.
It is also the second-largest and second-deadliest Ebola outbreakglobally, behind the 2014–2016 West African epidemic, which recorded about 28,600 cases and more than 11,000 deaths.
Reasons for hope
In a post on his official X account on Tuesday, Mohammed Janabi, the WHO Regional Director for Africa, said the rising figures reflected the toll the outbreak had taken on families and communities but noted that progress in recovery, research and response efforts offered reasons for hope.
Mr Janabi said more than 2,600 people had recovered, while new vaccine and treatment candidates were advancing through clinical trials.
He added that laboratory testing, treatment capacity, infection prevention and control, community engagement and surveillance were being strengthened to help contain the outbreak.
“Our teams are on the ground, working side by side with the government and partners to stop transmission and save lives,” he said, calling for sustained commitment, community trust and solidarity, as well as safe access to affected communities.
Spread beyond the DRC
The rising figures come amid growing concerns about the spread of the virus beyond the DRC, with Kenya and Nigeria reporting infections linked to the wider outbreak.
PREMIUM TIMES reportedlast week that Kenya had recorded nine confirmed cases, including two deaths, after the virus was introduced by a traveller who arrived from the DRC through Uganda.
Nigeria also confirmedits first Ebola case in more than a decade on 20 October, after a woman who had travelled from Uganda tested positive in the Federal Capital Territory (FCT).
In a subsequent report, PREMIUM TIMES reported that the Africa Centres for Disease Control and Prevention (Africa CDC) was investigating a possible link between the Nigerian case and the infection recorded in Kenya.
Both patients travelled through Entebbe International Airport in Uganda on 3 October, prompting investigations into whether they had shared equipment or had other contact. However, health officials have stressed that a direct connection between the infections has not been established.
Nigeria’s health minister, Muhammad Pate, later saidgenomic sequencing showed that the viruses detected in Nigeria and Kenya differed by only one mutation. He cautioned, however, that the finding did not establish where the Nigerian patient contracted the virus.
Contact tracing challenges
According to the Al Jazeera report, about 80 per cent of new cases in the DRC are occurring outside the known chains of transmission being monitored by health authorities.
This means many infections are being detected among people whose exposure to previously confirmed cases has not been established, complicating efforts to identify contacts and interrupt further transmission.
The Africa CDC has said at least 95 per cent of cases must be linked to known contacts of infected people for an outbreak to be considered under control.
Vaccine research underway
The absence of an approved vaccine against the Bundibugyo strain remains another major challenge in the response.
PREMIUM TIMES reportedon Friday that the World Health Organisation (WHO) had announced the commencement of the Tumaini clinical trial in Bunia, eastern DRC, to assess potential vaccines against the strain.
The trial began with the vaccination of its first participants on 23 October and is expected to evaluate several vaccine candidates, including Ervebo, which is licensed against a different Ebola virus species, as well as experimental candidates being developed by Moderna and the University of Oxford in collaboration with the Serum Institute of India.
The trial is intended to establish whether the candidates can safely generate an immune response and protect against the Bundibugyo virus. Their effectiveness against the strain has not yet been established.
The development follows an earlier WHO recommendation, reported by PREMIUM TIMES in August, that Ervebo be prioritised for a clinical trial after preliminary animal studies suggested it might offer some cross-protection against Bundibugyo virus disease.
Discover more from Premium Times Nigeria
Subscribe to get the latest posts sent to your email.
Insecurity has been identified as one of the “greatest obstacles” to containing the Ebola outbreak in the Democratic Republic of the Congo (DRC), where more than 11,000 cases and 5,400 deaths have been reported.
The World Health Organisation (WHO), in a news release publishedon 15 November, said attacks on health workers and facilities, displacement and difficulties reaching remote communities were disrupting efforts to contain the outbreak.
The outbreak, caused by the Bundibugyo virus, has spread to 67 health zones across eight provinces, with between 400 and 500 new cases reported weekly.
“Children account for more than a quarter of confirmed cases and one third of deaths. Seven in 10 children under five with confirmed Ebola have died,” it noted.
Attack on healthcare
According to the WHO, a recent armed attack in Cantine-Aloya killed 66 civilians, including three health workers, while three health facilities were looted.
The attack also resulted in more than 1,000 contacts being lost to follow-up, with three confirmed cases still unaccounted for. Another attack on the town was reported on 11 November.
According to WHO, more than 80 attacks on healthcare have been recorded since the outbreak was declared.
“A halt in hostilities is urgently needed to protect communities and health workers, and to safeguard the progress made over the past six months,” it noted.
The WHO said about two-thirds of confirmed deaths occurred in communities, suggesting that many infections were being identified too late for patients to receive timely treatment.
Cross-border transmission concerns
WHO also highlighted the risk of the outbreak spreading beyond the DRC, following recent imported cases in Kenya and Nigeria.
The agency said cross-border collaboration has strengthened surveillance, information-sharing and coordination among affected and at-risk countries.
“Recent imported cases in Kenya and Nigeria underscore the continuing risk of spread beyond national borders. Delays in paying frontline health workers and responders create tension and slow the response,” it said.
WHO said the developments underscored the need for neighbouring countries to maintain surveillance and preparedness, particularly around high-risk border areas.
Response gains
Despite the challenges, WHO said efforts had slowed transmission in some of the outbreak’s initial hotspots, including Mongbwalu, Nyankunde, Nizi, Rwampara and Butembo.
Diagnostic capacity has expanded from two laboratories to more than two dozen, while nearly 2,000 treatment beds are available across 104 treatment and transit centres.
About 3,000 people have recovered from the disease, while more than 17,000 community health workers and 46,000 community actors have been trained to support the response.
WHO said sustained funding, safe access for health workers and greater community participation would be essential to reaching areas that remain difficult to access and bringing the outbreak under control.
In Nigeria, the index patient evacuated to Switzerland has recovered and been discharged from hospital. At the same time, all 62 people identified as contacts have completed the mandatory 21-day monitoring period without any secondary infection.
The Nigeria Centre for Disease Control and Prevention (NCDC) disclosed this on 13 November, saying the patient tested negative for the virus after receiving further treatment in Switzerland.
NCDC Director-General, Jide Idris, said 13 of the 62 contacts developed fever or other symptoms during monitoring, but all tested negative. Seven suspected Ebola cases reported in five states were also investigated, with none testing positive.
“However, it is important to note that the completion of contact monitoring does not, by itself, constitute a formal declaration that an outbreak is over. Such a determination must be based on the applicable public health criteria and the findings of ongoing surveillance,” it noted.
“Nigeria therefore remains vigilant, particularly given the continued occurrence of Ebola virus disease in the DRC.”
Discover more from Premium Times Nigeria
Subscribe to get the latest posts sent to your email.
Médecins Sans Frontières (MSF) has warned that shortages of a lifesaving medicine are forcing medical teams to ration treatment for diphtheria patients in northern Nigeria, where more than 28,000 confirmed infections and 1,100 deaths have been reported this year.
The warning comes as figures attributed to the Nigeria Centre for Disease Control and Prevention (NCDC) show that the outbreak continues to spread, particularly among children who are unvaccinated or have not received all their recommended vaccine doses.
In a statement issued on Friday, MSF said supplies of diphtheria antitoxin (DAT), which neutralises the toxin responsible for potentially fatal complications, were dangerously low.
The organisation called on federal and state authorities, donors and international partners to urgently secure additional medicines and vaccines, ensure their timely clearance at ports and improve distribution to affected communities.
Treatment shortage threatens patients
MSF’s Medical Coordinator in Nigeria, David Kizito, warned that the shortage could compromise the treatment of severely ill patients.
“Our stocks are dangerously low, and we risk being unable to treat children and save lives as the outbreak continues,” he said.
MSF photograph of a healthcare worker examining a diphtheria patient at the Infectious Disease Hospital in Amanawa, Sokoto, on 8 October 2026
Diphtheria is a vaccine-preventable bacterial infection that can cause fever, sore throat and a thick membrane in the throat, sometimes obstructing breathing. Severe infections can damage the heart, nerves and kidneys.
According to the World Health Organisation (WHO), diphtheria antitoxin neutralises toxins circulating in the bloodstream, while antibiotics help eliminate the bacteria and reduce transmission.
Early administration of antitoxin is particularly important because it cannot reverse damage once the toxin has entered body cells.
MSF said limited global production and inconsistent availability had left treatment facilities struggling to obtain adequate supplies.
However, the organisation did not specify which facilities had exhausted their stocks, how many patients had been unable to obtain treatment or whether any deaths were directly attributable to the shortages.
Nigeria records 1,126 deaths
The warning comes amid a prolonged outbreak that began in late 2022.
PREMIUM TIMES reports that a situation report issued on 11 November by the International Federation of Red Cross and Red Crescent Societies(IFRC) and the Nigerian Red Cross Society, citing NCDC data, indicates that Nigeria recorded 37,529 suspected diphtheria cases, 28,151 confirmed infections and 1,126 deaths in 2026 as of 7 November.
The report said the outbreak had affected 26 states and the Federal Capital Territory, covering 361 local government areas.
Kano accounted for 12,008 confirmed cases, approximately 43 per cent of the national total.
The figures are substantially higher than those in MSF’s latest statement, which relied on NCDC statistics from 9 August, when 406 deaths had been reported for 2026.
The difference reflects reporting from separate periods and may include subsequent updates to surveillance records.
Katsina: 70 severe cases in 18 days
In Katsina State, MSF reported managing 86 diphtheria cases between 26 October and 12 November, including 70 classified as severe and 16 as non-severe.
Severe infections accounted for approximately 81 per cent of the patients managed by its teams during the period, although the figures do not represent the severity of all diphtheria infections recorded across the state.
MSF said its teams also reached 1,315 contacts through surveillance and contact-tracing activities. Of these, 1,301 received vaccinations, while 1,311 were given preventive antibiotics.
The organisation did not provide the locations of the cases or a breakdown of recoveries and deaths.
The development follows earlier concerns about the capacity of health facilities to manage the outbreak.
On 31 August, PREMIUM TIMES reported that the Federal Teaching Hospital (FTH), Katsina, was struggling with an influx of suspected and confirmed diphtheria patients, leaving its children’s ward under considerable pressure.
The hospital attributed the overcrowding partly to referrals from other facilities across the state.
In response, the federal government announced an emergency multi-agency task force to strengthen surveillance, immunisation and access to treatment in Katsina and Kano.
The intervention included plans to supply additional antitoxin, antibiotics, medical personnel and protective equipment to FTH Katsina.
Authorities also announced plans to establish treatment annexes across Katsina’s three senatorial districts — Katsina, Daura and Funtua — to reduce pressure on the referral hospital.
MSF’s latest statement did not indicate whether those facilities had become operational or how much additional antitoxin had been delivered since the intervention was announced.
Zamfara vaccine shortage
In neighbouring Zamfara State, MSF said its supported facilities in Gusau recorded more than 671 diphtheria admissions over approximately one month beginning on 6 October.
Most patients were children, while four out of every five had not been vaccinated.
The organisation also reported a substantial shortfall in vaccine supplies for an emergency immunisation campaign.
Of the 90,000 doses required, only 25,000 had been supplied, representing approximately 28 per cent of the stated requirement.
MSF said it was working with government health authorities to secure the outstanding doses and expand vaccination activities.
The shortfall highlights the continuing difficulties facing efforts to protect children against the disease.
In October, PREMIUM TIMES reportedthat the Executive Director of the National Primary Health Care Development Agency (NPHCDA), Muyi Aina, said about 93 per cent of children affected by recent diphtheria outbreaks had not received their full recommended vaccine doses.
Mr Aina said some had never been vaccinated, while others had received fewer than the three recommended doses. He identified misinformation and vaccine hesitancy among the challenges affecting immunisation uptake.
MSF’s response
Despite the challenges, MSF said its teams had treated more than 9,000 diphtheria patients through facility-based and community interventions since the beginning of its 2026 response.
In Kano, the organisation supported vaccination campaigns in April and June, administering more than 835,000 doses to children in partnership with the state Ministry of Health.
It also supported two vaccination rounds in Sokoto between February and April, reaching 49,018 children under 15.
The organisation said it was supporting treatment, surveillance, infection prevention and vaccination efforts in several northern states, alongside government health authorities.
MSF called for increased global production of diphtheria antitoxin and sustained investment in routine childhood immunisation to prevent further outbreaks.
The latest warning also draws renewed attention to the emergency measures announced by the federal government in August, particularly the delivery of antitoxin supplies and the proposed expansion of treatment facilities in Katsina.
The extent to which those interventions have improved access to treatment remains to be established.
Discover more from Premium Times Nigeria
Subscribe to get the latest posts sent to your email.